Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 6/20 | 0.67 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.65 |
| ▸ | GAA | P10253 | 2/20 | 0.65 |
| ▸ | POLB | P06746 | 2/20 | 0.65 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.65 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.65 |
| ▸ | ABL1 | P00519 | 1/20 | 0.65 |
| ▸ | ALPI | P09923 | 1/20 | 0.65 |
| ▸ | ALPG | P10696 | 1/20 | 0.65 |
| ▸ | APEX1 | P27695 | 1/20 | 0.65 |
| ▸ | CASP3 | P42574 | 1/20 | 0.65 |
| ▸ | RECQL | P46063 | 1/20 | 0.65 |
| ▸ | BLM | P54132 | 1/20 | 0.65 |
| ▸ | CASP7 | P55210 | 1/20 | 0.65 |
| ▸ | CASP6 | P55212 | 1/20 | 0.65 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.65 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.65 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.65 |
| ▸ | GSK3B | P49841 | 1/20 | 0.59 |
| ▸ | NPC1 | O15118 | 4/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16552778 | 0.88 | KMT2A (0.83) | KMT2AALDH1A1POLBL3MBTL1GSK3B | |
| SCHEMBL25706395 | 0.88 | L3MBTL1 (0.81) | KMT2AALDH1A1GAAPOLBL3MBTL1 | |
| SCHEMBL9419411 | 0.84 | KMT2A (0.69) | KMT2AALDH1A1L3MBTL1TDP1GSK3B | |
| SCHEMBL8402203 | 0.82 | KMT2A (0.67) | KMT2AALDH1A1L3MBTL1TDP1GSK3B | |
| SCHEMBL10854341 | 0.82 | KMT2A (0.67) | KMT2AALDH1A1POLBL3MBTL1GSK3B | |
| SCHEMBL507742 | 0.82 | HSD17B3 (0.69) | KMT2AALDH1A1L3MBTL1GSK3BNPC1 | |
| SCHEMBL3892731 | 0.81 | GSK3B (0.64) | KMT2AALDH1A1GAAL3MBTL1TDP1 | |
| SCHEMBL8269520 | 0.80 | KMT2A (0.77) | KMT2AALDH1A1GAAPOLBL3MBTL1 | |
| SCHEMBL15199328 | 0.80 | GSK3B (0.69) | KMT2AALDH1A1POLBGSK3BNPC1 | |
| SCHEMBL2325573 | 0.80 | KMT2A (0.64) | KMT2AALDH1A1POLBGSK3BNPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9259479-B2 | Treatment for comorbid diabetes with chronic kidney disease | ELI LILLY AND COMPANY (US) | 2016-02-16 | — | — | US | disclosed |
| US-20150111819-A1 | TREATMENT FOR COMORBID DIABETES WITH CHRONIC KIDNEY DISEASE | ELI LILLY AND COMPANY | 2015-04-23 | — | — | US | disclosed |
| WO-2013047092-A1 | PATTERN-FORMING METHOD, ELECTRON BEAM-SENSITIVE OR EXTREME ULTRAVIOLET RADIATION-SENSITIVE RESIN COMPOSITION, RESIST FILM, MANUFACTURING METHOD OF ELECTRONIC DEVICE USING THEM AND ELECTRONIC DEVICE | FUJIFILM CORPORATION (JP) | 2013-04-04 | — | — | WO | disclosed |
| EP-0542300-B1 | Method of preparing (S)-1-phenyl-1,3-propanediol or derivatives thereof | AJINOMOTO KK (JP) | 1997-02-26 | — | — | EP | disclosed |
| EP-0528244-B1 | Process for producing a beta-Ketoalcohol | AJINOMOTO KK (JP) | 1995-10-18 | — | — | EP | disclosed |
| US-5393664-A | Using a culture product | AJINOMOTO CO. INC. (JP) | 1995-02-28 | — | — | US | disclosed |
| US-5260486-A | Process for producing a beta-ketoalcohol | AJINOMOTO CO., INC. (JP) | 1993-11-09 | — | — | US | disclosed |
| EP-0542300-A2 | Method of preparing (S)-1-phenyl-1,3-propanediol or derivatives thereof | Ajinomoto Co., Inc. (JP) | 1993-05-19 | — | — | EP | disclosed |
| EP-0528244-A2 | Process for producing a beta-Ketoalcohol | Ajinomoto Co., Inc. (JP) | 1993-02-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150111819-A1 | TREATMENT FOR COMORBID DIABETES WITH CHRONIC KIDNEY DISEASE | GLP1R, SLC5A2, GPR119 | KMT2A 2732/4885ALDH1A1 2131/4885GAA 77/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.